In gene therapy, protamine sulfate's ability to condense plasmid DNA along with its approval by the U.S. Food and Drug Administration (FDA) have made it an appealing candidate to increase transduction rates by both viral[13] and nonviral (e.g. utilizing cationic liposomes)[14] mediated delivery mechanisms.